Efficacy and safety of low-dose rifampicin in patients with benign intrahepatic cholestasis
Background and aim: Some previous studies supported that rifampicin was an effective treatment for benign intrahepatic cholestasis. However, the efficacy and safety of rifampicin remain unclear. Therefore, this study aimed to evaluate its efficacy and safety on benign intrahepatic cholestasis. Metho...
Main Authors: | Xiaoyan Guo, Xinhua Li, Ying Yan, Huijuan Cao, Yufeng Zhang, Jing Lai |
---|---|
Format: | Article |
Language: | English |
Published: |
KeAi Communications Co., Ltd.
2022-09-01
|
Series: | Liver Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2542568422000423 |
Similar Items
-
The debut of benign recurrent intrahepatic cholestasis in acute hepatitis A
by: K. Yu. Kokina, et al.
Published: (2024-12-01) -
Case Report: A Rare Case of Benign Recurrent Intrahepatic Cholestasis-Type 1 With a Novel Heterozygous Pathogenic Variant of ATP8B1
by: Hiroyuki Suzuki, et al.
Published: (2022-04-01) -
Coronavirus disease 2019 (COVID‐19) as a potential trigger for benign recurrent intrahepatic cholestasis
by: Turan Çalhan, et al.
Published: (2022-03-01) -
A novel homozygous mutation in the USP53 gene as the cause of benign recurrent intrahepatic cholestasis in children: a case report
by: Burcu Berberoğlu Ateş, et al.
Published: (2023-12-01) -
Benign Recurrent Intrahepatic Cholestasis: Where Are We Now?
by: Eleni V. Geladari, et al.
Published: (2024-02-01)